LAG3 and cancer: Previous studies have shown that anti‐PD1 could enhance the cytotoxic effect of T cells by upregulating the T‐BET transcription,44, 45, 46 which lays the foundation of co‐targeting LAG3 and PD1 in cancer immunotherapy.